Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 996 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison control condition Clear all

Conditions: Anxiety, Panic Disorder
Interventions: Freespira Breathing System; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Treatment Resistant Depression
Interventions: VLS-01-203 BU, VLS-01-BU Placebo; Drug
Lead sponsor: atai Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 34
States / cities: Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 30 more

Conditions: Temporomandibular Joint and Muscle Disorder
Interventions: Biobehavioral, Active Coping/Attention Intervention; Behavioral
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: CBD, Hand Osteoarthritis
Interventions: CBD, Shea Butter; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Paul Carlson; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Controlled-Release Oxycodone Hydrochloride 40 mg tablet, OxyContin® 40 mg tablet; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Alzheimer's Disease
Interventions: GSK4527226, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 21
States / cities: San Diego, California • Lake Mary, Florida • Lake Worth, Florida + 16 more

Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more

Conditions: Attention Deficit Disorder
Interventions: Extended-release bupropion hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 21
States / cities: Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more

Conditions: Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability, COVID-19, Cardiac Arrest, Clinical Deterioration
Interventions: eCARTv5 clinical deterioration monitoring, Standard of care control; Device · Other
Lead sponsor: AgileMD, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: New Haven, Connecticut • Clearwater, Florida • Madison, Wisconsin

Conditions: Chronic Kidney Disease
Interventions: Education, Daily weight measurement and monitoring, Universal Dietary education, Medication review, Focused advanced directive program, Countdown to fistula program; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Plaque Psoriasis, Psoriasis Vulgaris
Interventions: Taclonex Ointment and Hydrogel Patch, Taclonex Ointment; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lower Limb Amputation Below Knee (Injury)
Interventions: Release/Relock Socket - In Lab, Release/Relock Socket - Out of Lab, Release/Relock Socket & Control; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: COVID-19
Interventions: NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine; Biological
Lead sponsor: CastleVax Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Colorado Springs, Colorado • Burlington, Massachusetts

Conditions: Alzheimer's Disease
Interventions: T3D-959, Placebo Comparator; Drug · Other
Lead sponsor: T3D Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions: FlorenceM, Medtronic insulin pump 640G; Device
Lead sponsor: University of Cambridge; Other
Eligibility: 6 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Aurora, Colorado • Minneapolis, Minnesota

Conditions: Plantar Fasciitis
Interventions: platelet rich plasma, corticosteroid injection; Biological · Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Bernadino, California

Conditions: Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions: VP-102 and applicator, Placebo; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more

Conditions: Schizophrenia
Interventions: Virtual reality social skills training; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Etelcalcetide, Cinacalcet, Oral Placebo, Intravenous Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 41
States / cities: Azusa, California • Bakersfield, California • Chula Vista, California + 37 more

Conditions: Program Sustainability, Tobacco Use
Interventions: Program Sustainability Action Planning Model and Training Curricula; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Arthritis, Juvenile Idiopathic
Interventions: Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Cognitive Processing Therapy (CPT); Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Hines, Illinois • Madison, Wisconsin

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: losmapimod, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Birmingham, Alabama • Torrance, California • Rochester, Minnesota + 5 more

Search by objective public record fields.

The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

An Implementation and Biobehavioral Study of Temporomandibular Joint and Muscle Disorder (TMJMD)

Is Topical CBD Effective in Treating Thumb Joint Arthritis

Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression

Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning

Healthy Transitions in Late Stage Kidney Disease

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

NIH Release/Relock Socket

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

Home Testing of Day and Night Closed Loop With Pump Suspend Feature

Treatment of Plantar Fasciitis With Platelet Rich Plasma

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

Virtual Reality Training for Social Skills in Schizophrenia

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

Evaluating and Improving the Sustainability of State-level Tobacco Control Programs in the United States

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

Comparison of Videoconference and Face-to-Face Delivery of Cognitive Processing Therapy for Posttraumatic Stress Disorder

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).